Skip to main content
Clinical Trials/ISRCTN86185157
ISRCTN86185157CompletedPhase 3

A multicentre randomised trial of single dose Radiotherapy compared to Ibandronate for localised metastatic Bone pain

Cancer Research UK (CRUK) (UK)0 sites580 target enrollmentStarted: June 2, 2003Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
580

Study Overview

Brief Summary

2015 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26242893 results

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Histologically or cytologically proven underlying primary malignancy of breast, lung or prostate, or sclerotic bone metastases in a patient presenting with a serum Prostate Specific Antigen (PSA) more than 100ng/ml
  • 2. Bone metastases confirmed radiologically on plain x-ray, isotope scan, Computed Tomography (CT) or Magnetic Resonance (MR) scan
  • 3. Single localised metastatic bone pain receiving optimal analgesics and adjuvant drugs including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) unless contraindicated.
  • 4. Clinical diagnosis of metastatic bone pain for which radiotherapy is indicated
  • 5. Aged over 18 yrs with no upper age limit
  • 6. Able to comply with pain chart and quality of life assessments
  • 7. Able to give written informed consent.

Exclusion Criteria

  • 1. Predicted life expectancy less than three months
  • 2. Bisphosphonate treatment within the last six months
  • 3. Any previous treatment that contraindicated radiotherapy or ibandronate or that would interfere with the action of either
  • 4. Unfit to receive radiotherapy and ibandronate
  • 5. Aspirin sensitive asthma in past medical history
  • 6. Pregnancy and lactation

Investigators

Sponsor
Cancer Research UK (CRUK) (UK)

Similar Trials